GLP-1 Receptor Agonists: A Comprehensive Comparison for Prescribers

If you've been researching GLP-1 medications, you've probably noticed that the landscape is confusing. Semaglutide, tirzepatide, liraglutide, dulaglutide — they all sound vaguely similar, they're all injectable, and they all promise weight loss or blood sugar control or both. But they're not interchangeable, and understanding the differences can help you have a more informed conversation with your provider about which one makes sense for you. Let's break down the major players in plain English, with the clinical evidence to back it up.

The GLP-1 Landscape: How We Got Here

GLP-1 receptor agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone your gut naturally releases after you eat. This hormone does several useful things: it stimulates insulin release, suppresses glucagon (a hormone that raises blood sugar), slows how fast your stomach empties, and signals your brain that you're full.¹ The first generation of these drugs — like exenatide (Byetta) and liraglutide (Victoza) — were primarily developed for type 2 diabetes. But as researchers realized that these medications also caused significant weight loss, a new generation emerged specifically targeting obesity. Today, the field is dominated by four main options, each with its own strengths and trade-offs.

Semaglutide (Ozempic / Wegovy)

Semaglutide is probably the drug that brought GLP-1 medications into mainstream conversation. It's a once-weekly injection that works as a pure GLP-1 receptor agonist — meaning it targets only the GLP-1 receptor. For weight loss, the STEP trial program is the gold standard. In STEP 1, participants receiving semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks, compared to roughly 2.4% in the placebo group.² That's a dramatic difference, and it established semaglutide as a serious weight loss medication rather than just a diabetes drug with a side benefit. But semaglutide's story goes beyond the scale. The SELECT trial — a massive cardiovascular outcomes study — showed that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with overweight or obesity who already had cardiovascular disease, even if they didn't have diabetes.³ That's a landmark finding. It means semaglutide isn't just helping people lose weight — it's potentially protecting their hearts. The side effect profile is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation. These are generally manageable with slow dose escalation and tend to improve over time. The medication is titrated up gradually from 0.25 mg to the full 2.4 mg dose over several months.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is the newer kid on the block, and it's made quite an entrance. What makes it unique is that it's a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.⁴ The theory is that hitting two incretin pathways simultaneously produces greater metabolic effects than targeting GLP-1 alone. The SURMOUNT trial program put this theory to the test, and the results were impressive. In SURMOUNT-1, the highest dose of tirzepatide (15 mg) produced an average weight loss of about 20.9% over 72 weeks — significantly more than what was seen with semaglutide in the STEP trials.⁴ Some participants lost even more, with roughly half of those on the highest dose losing 20% or more of their body weight. The side effect profile is broadly similar to semaglutide: gastrointestinal symptoms are the most common complaint. What's interesting is that tirzepatide seems to achieve greater weight loss at doses that are generally well-tolerated, though direct head-to-head comparisons are still ongoing (the SURMOUNT-5 trial is comparing tirzepatide and semaglutide directly). The big question mark with tirzepatide is cardiovascular outcomes. While semaglutide has the SELECT trial data showing hard cardiovascular endpoints, tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) was completed and showed it was non-inferior to dulaglutide for major cardiovascular events in people with type 2 diabetes. The dedicated obesity cardiovascular outcomes trial is still maturing.

Liraglutide (Victoza / Saxenda)

Liraglutide is the veteran of the group. It was approved for diabetes (as Victoza) in 2010 and for weight management (as Saxenda) in 2014, giving it the longest track record of any GLP-1 medication for obesity.⁵ The SCALE trial showed that liraglutide 3.0 mg produced an average weight loss of about 8% over 56 weeks — modest compared to semaglutide and tirzepatide, but still clinically meaningful. The trial also showed that liraglutide significantly reduced the risk of progressing from prediabetes to type 2 diabetes. The main practical difference is dosing: liraglutide is a daily injection rather than weekly. For some people, this is a dealbreaker. For others, the daily routine actually helps them stay consistent. The side effect profile is similar to other GLP-1 RAs, with nausea being the most common issue. Where liraglutide shines is its safety data. With over a decade of real-world use, we have more long-term safety information on liraglutide than on any other GLP-1 medication. For risk-averse patients or providers, this track record matters.

Dulaglutide (Trulicity)

Dulaglutide is a once-weekly GLP-1 RA primarily indicated for type 2 diabetes. It's not specifically approved for weight management, but it does produce modest weight loss — typically in the range of 3–6% depending on the dose.⁶ The REWIND trial showed that dulaglutide reduced major cardiovascular events in people with type 2 diabetes, including many who had established cardiovascular disease. This cardiovascular benefit, combined with its weekly dosing and generally tolerable side effect profile, makes it a popular choice for people whose primary goal is blood sugar management with some weight loss as a bonus. For weight loss specifically, dulaglutide is the least potent of the four options discussed here. But for people with type 2 diabetes who want better blood sugar control, cardiovascular protection, and some weight loss — without necessarily pursuing aggressive weight management — dulaglutide is a well-established choice.

How They Compare: A Side-by-Side Look

Weight loss effectiveness, ranked from most to least potent:

• Tirzepatide 15 mg: ~21% average weight loss (SURMOUNT-1)⁴
• Semaglutide 2.4 mg: ~15% average weight loss (STEP 1)²
• Liraglutide 3.0 mg: ~8% average weight loss (SCALE)⁵
• Dulaglutide 4.5 mg: ~3–6% average weight loss (REWIND/AWARD)⁶ Dosing frequency:
• Weekly: Semaglutide, tirzepatide, dulaglutide
• Daily: Liraglutide Cardiovascular evidence:
• Semaglutide: Strongest evidence — SELECT trial showed 20% reduction in MACE in people with obesity and cardiovascular disease (with or without diabetes)³
• Tirzepatide: Non-inferior to dulaglutide in SURPASS-CVOT for type 2 diabetes; dedicated obesity CV outcomes data still maturing
• Liraglutide: LEADER trial showed cardiovascular benefit in type 2 diabetes
• Dulaglutide: REWIND trial showed cardiovascular benefit in type 2 diabetes Side effect profiles are broadly similar across all four, with GI symptoms (nausea, vomiting, diarrhea, constipation) being the most common. The intensity and frequency of side effects generally track with potency — the medications that produce more weight loss tend to produce slightly more GI discomfort, particularly during dose escalation.

So Which One Should You Choose?

This is the question everyone wants answered, and the honest response is: it depends on your specific situation. Here's how to think about it: If maximum weight loss is your primary goal, tirzepatide currently leads the pack based on the available clinical trial data. The SURMOUNT numbers are impressive, and for people with significant obesity, that extra weight loss can translate into meaningful health improvements. If you have cardiovascular disease and obesity, semaglutide has the strongest evidence base right now. The SELECT trial is the first and (so far) only trial to demonstrate that a GLP-1 medication can reduce cardiovascular events in people with obesity who don't have diabetes. That's a powerful differentiator. If you value a long safety track record, liraglutide has been on the market the longest and has the most real-world safety data. Its efficacy is more modest, but some people and providers prioritize what's known over what's newer. If type 2 diabetes management is your primary concern, both semaglutide and tirzepatide have excellent glucose-lowering data, and tirzepatide's dual mechanism may offer additional benefits for insulin sensitivity. Dulaglutide is also a solid choice with proven cardiovascular benefits. If cost and insurance coverage are major factors, this is where the conversation gets real. These medications can be expensive, and insurance coverage varies widely. Semaglutide and tirzepatide are generally the most expensive options, though compounding pharmacies and manufacturer discount programs can help. Talk to your provider and your insurance company about what's actually accessible to you.

The Bottom Line

The GLP-1 receptor agonist class has matured from a niche diabetes treatment into a powerful tool for weight management and metabolic health. Each medication in the class has its own strengths, and the "best" choice depends on your health profile, goals, and practical considerations like cost and dosing preference. The most important thing is to have an honest conversation with your healthcare provider about what you're hoping to achieve and what risks you're comfortable with. These medications are tools — powerful ones — but they work best as part of a comprehensive approach that includes nutrition, physical activity, and ongoing medical supervision.

References

[1] Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PubMed [2] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed [3] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed [4] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed [5] Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PubMed [6] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. PubMed

This article is for educational purposes. Always discuss medication choices with your healthcare provider and consult current prescribing information.